Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024)
Ligand Pharmaceuticals' (LGND) quarterly Raw Materials came in at $603000.0 in Q4 2024, up 43.57% year-on-year from $420000.0 in Q1 2024, and down 75.83% quarter-over-quarter from $2.5 million in Q3 2024.
Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024) Analysis & Trends
Ligand Pharmaceuticals has disclosed Raw Materials across 2 years of filings, most recently posting $603000.0 for Q4 2024.
- Raw Materials for Q4 2024 came in at $603000.0, up 43.57% year-over-year; the trailing twelve-month figure through Dec 2024 was $603000.0 (up 43.57% YoY), and the FY2024 annual result was $603000.0, up 43.57% from the prior year.
- Raw Materials came in at $603000.0 for Q4 2024 at Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $2.5 million in Q3 2024 to a low of $420000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Dec 31, 2023 | 420,000.00 |